• Needham has initiated coverage on Day One Biopharmaceuticals Inc (NASDAQ: DAWN) with a Buy rating and a price target of $40.
• Day One's lead product candidate, tovorafenib, is under development for relapsed or progressive pediatric low-grade glioma (pLGG), the most common brain tumor diagnosed in children.
• Initial data demonstrated an overall response rate (ORR) of 64% and a clinical benefit rate (CBR) of 91%.
• The analyst writes that Tovorafenib could become a best-in-class RAF inhibitor for pLGG and will be the only approved, targeted therapy for 85% of the BRAF population with no options other than chemo. 
• Needham estimates over $2 billion in global sales in 2035, driven by approval in 1L and 2L pLGG, and assigns a probability of success of 50% and 65%, respectively. 
• The analyst also says that Tovo's dosing frequency of once weekly compares favorably to the competitors' QD (once daily) or BID (twice daily) dosing.
• Price Action: DAWN shares are up 3.88% at $20.88 on the last check Wednesday.

Latest Ratings for DAWN

View More Analyst Ratings for DAWN

View the Latest Analyst Ratings

See more from Benzinga

• Cytokinetics AdComm Outcome Might Be Blessing In Disguise, This Analyst Said
• Comparing With Pfizer's Vaccine, Icosavax RSV Candidate 'Could Establish Differentiation,' Analyst Says
• Trump Vs. DeSantis: Republicans Have A Clear Favorite In New Poll

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.